Felbamate Shortage: What Providers and Prescribers Need to Know in 2026

Felbamate is one of the most tightly restricted antiepileptic drugs in clinical practice—and with good reason. Its black box warnings for aplastic anemia and hepatic failure mean that only patients for whom the benefit of seizure control clearly outweighs these serious risks should ever be on it. But that small population of patients needs reliable, uninterrupted access. When supply problems arise, the consequences can be severe: uncontrolled seizures, emergency department visits, or dangerous abrupt discontinuation.

This article provides a clinical overview of felbamate's availability landscape in 2026, including the root causes of the current access challenges, supply chain considerations, clinical contingency planning, and practical tools to help your patients avoid dangerous medication gaps.

Current Felbamate Availability Status (2026)

As of 2026, felbamate does not appear on the FDA's official Drug Shortages Database. However, this designation does not reflect the reality that most retail pharmacies do not stock felbamate at all. The drug's severely restricted use—driven by its post-approval safety profile—means prescription volume is far too low to incentivize most chain pharmacies to maintain standing inventory.

Generic felbamate has been available since 2011, manufactured by a small number of companies including Alvogen, Taro, and Par Pharmaceutical. Supply exists in wholesale distribution networks, but it requires active ordering by individual pharmacies. This is a critical distinction from shortage drugs, where supply does not exist at any level of the chain. Patients can obtain felbamate—but they need to know where to look and often need advance planning.

Why Felbamate Access Is Challenging: A Clinical Perspective

Several structural factors make felbamate access challenging for your patients:

Low prescription volume. The same black box profile that makes felbamate a last-resort option reduces its market volume to the point where pharmacies have little reason to stock it proactively.

Pharmacy deserts and closures. An estimated 2,700 U.S. pharmacies have closed in the past two years. For patients in rural or underserved areas, each closure reduces the number of potential dispensing points for a medication that was already rarely stocked.

Documentation requirements. The mandatory Patient/Physician Acknowledgment Form creates workflow friction at both the prescribing and dispensing levels. Some pharmacies unfamiliar with felbamate's requirements may delay dispensing while they confirm documentation.

Insurance prior authorization. Given its black box profile and restricted use criteria, felbamate often requires prior authorization from insurance plans. PA denials or delays can create dangerous gaps, particularly for patients whose coverage changes.

Monitoring Requirements Every Prescriber Must Know

Before initiating and throughout felbamate therapy, the following monitoring is required:

Written informed consent (Patient/Physician Acknowledgment Form) before the first prescription

Baseline CBC with reticulocyte count

Baseline serum AST and ALT (do not initiate if liver enzymes are elevated)

Frequent CBC and liver function monitoring during therapy and for a significant period after discontinuation

Discontinue if AST or ALT reaches ≥2x the upper limit of normal, or if clinical liver injury signs emerge

Discontinue and consult hematology if bone marrow depression is detected

The target serum concentration for felbamate is 30–60 mg/L. Note that both aplastic anemia and hepatic failure may occur insidiously, typically in the first 6–12 months, but can develop later. There is no known way to predict or reliably prevent these reactions.

Drug Interactions to Consider When Managing Patients on Felbamate

Felbamate has significant pharmacokinetic interactions with other antiepileptic drugs (AEDs). These must be managed carefully, especially when initiating, adjusting, or transitioning therapy:

Felbamate increases levels of: phenytoin (dose reduction ~40% often required), valproic acid (~54% increase at full dose), phenobarbital

Felbamate decreases levels of: carbamazepine (while increasing the active epoxide metabolite)

Enzyme-inducing AEDs (carbamazepine, phenytoin) decrease felbamate levels by approximately 40–45%; valproic acid and gabapentin increase felbamate levels

When adding or removing felbamate from a patient's regimen, expect to adjust doses of concurrent AEDs by 20–33%. Monitor plasma levels where available.

Clinical Contingency Planning for Felbamate Supply Gaps

If a patient reports they cannot find felbamate, the clinical priority is preventing abrupt discontinuation. Recommended steps:

Verify the actual supply situation. Many patients only check one or two pharmacies. Direct them to hospital pharmacies, request a special order from their current pharmacy, or use medfinder to identify nearby locations with stock.

Provide office samples if available. If your practice maintains samples, providing a short bridge supply while the patient secures their prescription is appropriate.

Initiate a controlled taper only if supply truly cannot be obtained. Gradually reduce dose while monitoring for seizure breakthrough. Document your clinical rationale for any transition or taper.

Discuss alternatives in the context of the patient's full seizure history. Cenobamate (Xcopri), lamotrigine, rufinamide, cannabidiol (Epidiolex), and clobazam may be appropriate depending on the patient's seizure type and prior medication history.

How medfinder Supports Your Patients

Referring patients to medfinder is a practical way to reduce the burden on your staff when patients call in about supply problems. medfinder contacts local pharmacies on the patient's behalf to identify which ones have felbamate in stock, then texts results directly to the patient. This reduces back-and-forth calls to your office and gets patients to the right pharmacy faster.

For a comprehensive guide to supporting patients with access, see How to Help Your Patients Find Felbamate in Stock: A Provider's Guide.